Adverse Events During Immunotherapy Against Grass Pollen-Induced Allergic Rhinitis: Differences Between Subcutaneous and Sublingual Treatment
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Adverse Events During Immunotherapy Against Grass Pollen-Induced Allergic Rhinitis : Differences Between Subcutaneous and Sublingual Treatment. / Aasbjerg, Kristian; Dalhoff, Kim Peder; Backer, Vibeke.
I: Basic & Clinical Pharmacology & Toxicology, Bind 117, Nr. 2, 08.2015, s. 73-84.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Adverse Events During Immunotherapy Against Grass Pollen-Induced Allergic Rhinitis
T2 - Differences Between Subcutaneous and Sublingual Treatment
AU - Aasbjerg, Kristian
AU - Dalhoff, Kim Peder
AU - Backer, Vibeke
N1 - © 2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
PY - 2015/8
Y1 - 2015/8
N2 - Allergic rhinitis (AR) triggered by grass pollen is a common disease, affecting millions of people worldwide. Treatment consists of symptom-alleviating drugs, such as topical corticosteroids or antihistamines. Another option is potentially curative immunotherapy, currently available as sublingual and subcutaneous treatment. We investigated the potential differences in the prevalence and severity of adverse events related to subcutaneous and sublingual immunotherapy (SLIT) against grass pollen-induced AR. A thorough literature search was performed with PubMed and EMBASE. The findings were compared with the available summaries of product characteristics (SPC) and with commercial pharmacology databases (Micromedex). The majority of available safety data originate from registered products of standardized allergens. A surprisingly large percentage of drugs, especially those used in the United States, have no systematically collected safety data. No sufficiently powered randomized trials comparing sublingual and subcutaneous immunotherapy (SCIT) were available, but general safety assessments indicate that sublingual tablet treatment is safer than subcutaneous treatment. Not all commonly used immunotherapy drugs are officially registered, and not all have systematically collected safety data. This is especially true for older drugs used in the United States. In contrast, newer drugs that have undergone extensive clinical testing have better documentation, but unified collection of safety data is still lacking. Considering the evidence available, most drugs elicit similar side effects from the same organ systems, and symptoms from the sublingual drug classes are probably less severe. However, a head-to-head comparison of safety and efficacy is lacking.
AB - Allergic rhinitis (AR) triggered by grass pollen is a common disease, affecting millions of people worldwide. Treatment consists of symptom-alleviating drugs, such as topical corticosteroids or antihistamines. Another option is potentially curative immunotherapy, currently available as sublingual and subcutaneous treatment. We investigated the potential differences in the prevalence and severity of adverse events related to subcutaneous and sublingual immunotherapy (SLIT) against grass pollen-induced AR. A thorough literature search was performed with PubMed and EMBASE. The findings were compared with the available summaries of product characteristics (SPC) and with commercial pharmacology databases (Micromedex). The majority of available safety data originate from registered products of standardized allergens. A surprisingly large percentage of drugs, especially those used in the United States, have no systematically collected safety data. No sufficiently powered randomized trials comparing sublingual and subcutaneous immunotherapy (SCIT) were available, but general safety assessments indicate that sublingual tablet treatment is safer than subcutaneous treatment. Not all commonly used immunotherapy drugs are officially registered, and not all have systematically collected safety data. This is especially true for older drugs used in the United States. In contrast, newer drugs that have undergone extensive clinical testing have better documentation, but unified collection of safety data is still lacking. Considering the evidence available, most drugs elicit similar side effects from the same organ systems, and symptoms from the sublingual drug classes are probably less severe. However, a head-to-head comparison of safety and efficacy is lacking.
KW - Administration, Sublingual
KW - Allergens
KW - Humans
KW - Immunotherapy
KW - Injections, Subcutaneous
KW - Poaceae
KW - Pollen
KW - Rhinitis, Allergic, Seasonal
U2 - 10.1111/bcpt.12416
DO - 10.1111/bcpt.12416
M3 - Journal article
C2 - 25968654
VL - 117
SP - 73
EP - 84
JO - Basic and Clinical Pharmacology and Toxicology
JF - Basic and Clinical Pharmacology and Toxicology
SN - 1742-7835
IS - 2
ER -
ID: 160445585